For instance, a study utilizing data from the United Kingdom Clinical Practice Research Datalink (UK CPRD) suggested an increased risk of intestinal obstruction in T2DM patients prescribed GLP-1RAs compared to those prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors [15]. This evidence concerns the gene SLC5A2 and intestinal obstruction.